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Background
In association with aspirin, clopidogrel, an irreversible antagonist of the ADP receptor subtype P2Y12, has become a mainstay for treatment of ACS [1] . However, recurrent ischaemic events continue to occur, suggesting an inadequate effect of antiplatelet therapy [2] in some patients. The antiplatelet effect of clopidogrel has shown a marked interindividual variability of response [3] , and as with aspirin, the concept of low responsiveness to clopidogrel has been evoked in the literature [4, 5] . Currently the validity of and agreement on the definition for this concept remain unclear. Moreover, the clinical implications of this variability require further investigation [6, 7] . In most studies, platelet function is measured in vitro by light-transmission aggregometry, which presents some drawbacks. Firstly, platelet aggregometry requires the preparation of platelet-rich plasma, which is timeconsuming and susceptible to artefacts [8] . Furthermore, clinical studies using platelet aggregometry to monitor antiplatelet therapy have found an interlaboratory variability up to 30% [9] . Given the serious consequences of such a poor response, many authors have expressed a need for a platelet function test that could provide a reliable evaluation of clinical efficacy. This test must be easy to perform in practice, and specifically monitor the antiaggregatory effect of clopidogrel.
In platelets, measurement of VASP phosphorylation, an intracellular actin protein, is correlated with blockade of the P2Y12 receptor by clopidogrel. As demonstrated recently, this assay has a high sensitivity and specificity for monitoring clopidogrel treatment in patients with ischaemic cardiovascular disease and a good correlation with platelet aggregation [10, 11] . The advantages of this method include its simplicity and speed. The assay can be performed on only 30 L of whole blood and the results are usable within 30 minutes. Moreover, the VASP assay directly measures the function of the clopidogrel target, the P2Y12 receptor, rather than the effects of the other platelet inhibitors [12] . A recent study has suggested that this assay can discriminate patients at high risk of coronary stent thrombosis despite receiving treatment with clopidogrel [13] .
The objective of this study was to evaluate at the bedside the prognostic value of clopidogrel response using flowcytometric assessment of VASP in ACS without persistent ST-segment elevation.
Methods

Study population
Between December 2004 and April 2005 we prospectively studied 49 consecutive patients with non-ST-segment elevation ACS. Study inclusion required that patients had undergone coronary angiography within 24 hours of admission for a history of unstable angina with ST-segment depression greater than 0.05 mV or transient ST-segment elevation or T-wave inversion and/or elevated levels of troponin I above 0.04 ng/mL. The exclusion criteria were active bleeding or bleeding diathesis, prior clopidogrel therapy or administration of a glycoprotein (GP) IIb/IIIa inhibitor within the previous 14 days. All patients were administered a 300 mg loading dose of clopidogrel followed by 75 mg per day, associated with 75 mg aspirin daily. The combination of clopidogrel and aspirin therapy was maintained for 9 months. This study was performed in accordance with standard practice in our hospital, and GP IIb/IIIa inhibitors (tirofiban or eptifibatide) were administered prior to coronary angiography when the Thrombolysis In Myocardial Infarction (TIMI) risk score was greater or equal to 4, corresponding to high-risk patients [14] .
All patients were enrolled after providing written informed consent. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki.
In patients who underwent surgery, clopidogrel was discontinued five days before surgery and reinitiated five days after.
Blood samples
Blood samples were collected in evacuated tubes containing 0.105 M of trisodium citrate before starting clopidogrel treatment (day 0 = baseline), and at days 1 and 4 after starting clopidogrel therapy.
We determined the VASP phosphorylation status of whole blood using a standardized flow cytometric assay (PLT VASP/P2Y12 ® ; Diagnostica Stago, Biocytex, Asnières, France) adapted from the method by Schwarz et al. [15] . The citrated blood samples were incubated with PGE1 or PGE1 and ADP for 10 minutes and fixed with paraformaldehyde for 5 minutes. Cells were made permeable and stained with antiserine 239-phosphorylated VASP (clone 16C2) for 5 minutes, and then with polyclonal goat antimouse immunoglobulin G and platelet marker antiCD61-PE for 5 minutes. The MFI was assessed with a Becton Dickinson FacsCANTO (Becton Dickinson, San Jose, California, USA). The PRI was calculated by measuring the VASP phosphorylation levels after stimulation with PGE1 and also PGE1 + ADP according to the formula:
Schematically, PGE1 increased the VASP phosphorylation levels by stimulation of adenylate cyclase. The addition of ADP to PGE1-stimulated platelets reduced the PGE1-induced VASP phosphorylation levels. A ratio of 100% indicated complete absence of clopidogrel effect; a decrease in the ratio demonstrated some degree of clopidogrel-induced inhibition of the P2Y12 receptor.
Definition and clinical outcomes
Compliance with drug therapy was assessed 1 month after discharge. Patients were contacted via telephone calls 6 months after discharge from hospital to determine the occurrence of adverse cardiovascular events. The clinical endpoints included cardiovascular death, rehospitalization for stent thrombosis defined as angiographically documented total occlusion at the lesion site within 30 days of the initial procedure, ischaemic stroke and recurrent ACS. Outcomes of the perioperative period were not entered for these patients because clopidogrel had been discontinued before surgery.
Statistical analysis
All statistical analysis was performed with SAS statistical software (version 8.2, Cary, NC, USA). Results are presented as mean ± S.D. for continuous variables and as percentage for categorical variables. Patients were stratified into four quartiles according to the PRI of VASP after four days. Categorical variables were measured for linear trends with the Cochran-Armitage test. Differences in continuous variables between groups were compared using the t test. Evolution of PRI of VASP was assessed using Wilcoxon's matched-pairs signed-rank test. Proportions were compared with the chisquare test or Fisher's exact test when appropriate. Receiver operator curves (ROC) were generated using GraphPad Prism 5. Areas under the ROC (AUC) for troponin, day 1 and day 4 VASP were compared according to DeLong et al. method [16] , first grouped, then each with another, using the Bonferroni method to account for multiple testing. A p value less than 0.05 was considered statistically significant.
Results
Patients' characteristics
A total of 49 patients were included in our study; their demographic, baseline and treatment characteristics are shown in Table 1 . 
VASP phosphorylation in the study population
We analysed platelet response to clopidogrel using the percentage of PRI of VASP at three different times. Analysis of VASP (mean ± S.D.) showed a decreased PRI time: 86 ± 6% before treatment, 71 ± 13% at day 1 and 61 ± 16% at day 4 (p < 0.001). The evolution of PRI of our population is shown in Fig. 1 . Significant interindividual variability was noted, especially after four days of treatment, with the S.D. ranging from 19 to 84%. The interindividual variability of PRI of VASP after clopidogrel therapy is also presented in Fig. 1 .
Variability in platelet response to clopidogrel
Patients were stratified into four quartiles according to the percentage of PRI of VASP at day 4. Patients in the fourth quartile were defined as low responders to clopidogrel. The values and main characteristics of the different quartiles are presented in Table 2 . 
Clinical outcomes
Six-month follow-up data were complete in all 49 patients. Six cardiovascular events occurred within six months of discharge (three cardiovascular deaths, one ACS, one stent thrombosis, one ischaemic stroke). All events occurred during aspirin and clopidogrel therapy. Five of these events occurred in the fourth quartile and one in the third quartile. The characteristics of these populations are presented in Table 1 . The PRI of VASP before treatment was comparable in both populations 86% ± 6 (group 1 = no cardiovascular events) versus 86 ± 5% (group 2 = cardiovascular events). At day 1, the differences were already significant: 70 ± 14% (group 1) versus 79 ± 8% (group 2; p = 0.05). At day 4, the PRI was significantly higher in the group with cardiovascular events: 59 ± 16% (group 1) versus 76 ± 3% (group 2; Patients with a cardiovascular event had no significant decrease in PRI of VASP between days 0 and 4 (p = 0.06). p = 0.006). Patients in group 2 had no significant decrease of the PRI of VASP between day 0 and day 4 (p = 0.06; Fig. 2) , in contrast to patients without a cardiovascular event (group 1) who showed a significant decrease of the PRI of VASP (p < 0.001).
ROC determination
The AUC of the PRI of VASP at days 1 and 4 and for troponin level on admission as diagnostic tests for clinical cardiovascular events were, respectively, 74% (95% confidence interval [CI] 51-98), 84% (95% CI 63-100) and 55% (95% CI 30-81; Fig. 3A-C) . Comparisons of global AUC showed a statistically significant difference between PRI of VASP at day 4 and troponin (p < 0.01). PRI of VASP at day 4 appeared to provide the best ROC curve to predict absence of clinical events: the best cut-off value for PRI of VASP was 70%, with 100% sensitivity and 69% specificity, providing a 100% negative predictive value for cardiovascular events.
Discussion
This current study confirms that assessment of the VASP index can be used to evaluate the efficacy of clopidogrel therapy and identify low responders to clopidogrel therapy. This study suggests an association between low response to clopidogrel therapy and recurrence of cardiovascular events.
Previous studies had shown that analysis of VASP appears to be an effective method of monitoring response to clopidogrel, with a good correlation between the VASP index and the result obtained with platelet aggregometry [11, 13] . Moreover, the VASP test has technical advantages compared with aggregometry. The use of standardized kits lowers interobserver dependence on the test. Furthermore, this test can be performed in less than 1 hour. Finally, its main advantage is the stability of the blood sample, which can be stored at room temperature for up to 24 hours before processing, which offers convenient flexibility for routine clinical practice.
In the present study, cytometric analysis of VASP phosphorylation confirmed a significant stepwise decrease of the VASP index from baseline to day 4. These results are comparable to those of Aleil et al. [11] , who reported a significant decrease of the PRI of VASP after clopidogrel treatment. It is noteworthy to observe that in our study, analysis of VASP phosphorylation provided an incomplete response after 1 day of clopidogrel treatment. Furthermore, the difference of PRI of VASP observed between patients with or without cardiovascular events was weak when this test was performed after only 24 hours of clopidogrel therapy. This difference became highly significant only after four days of clopidogrel therapy. Hence our data demonstrate that early measurement of PRI of VASP is of no value and suggests that the accuracy of the VASP index is optimal after more than 48 hours. This finding has not been reported previously with other biological tests such as light transmission aggregometry -the gold standard method of assessing biological response to clopidogrel. To our knowledge, the reasons for the delay observed with VASP are unknown.
The use of a clopidogrel loading dose above 300 mg may enable the VASP index to be measured earlier. In a recent study, Bonello et al. [17] evaluated the impact of additional loading doses of clopidogrel according to the VASP index in patients with clopidogrel resistance. In their study, VASP was measured 24 hours after a 600 mg loading dose of clopidogrel. A lower rate of major adverse cardiac events was recorded in the VASP-guided group, demonstrating the value of adjusted clopidogrel loading dose according to VASP index after only 24 hours.
Currently, there is no agreement on the definition of low response to clopidogrel using a biological test and especially with cytometric VASP analysis. Barragan et al. [13] considered that patients who had a PRI of VASP greater than 50% were low responders. For Aleil et al. [11] , patients who had a PRI of VASP equivalent to that for patients not taking clopidogrel were classified as poor responders, corresponding to 30% of individuals. In our study, as in that by Matetzky et al. [7] , we chose to stratify the population into quartiles of response. Patients in the fourth quartile, corresponding to 25% of the population, were defined as low responders to clopidogrel. Five of the six cardiovascular events were observed in the low-responder group. There were no significant differences in the demographic and clinical characteristics of patients with or without ischaemic events, except for a higher rate of hypertension in the population without cardiovascular events. Concerning the infrequent use of GP IIb/IIIa inhibitors in our study, it should be noted that their use was guided by the TIMI risk score and concerned 20% of our patients. Among the patients who had a cardiovascular event, according to the TIMI risk score, one should have benefited from GP IIb/IIIa inhibitor therapy but he had a contraindication to this therapy. Nevertheless, adjustment for the use of a GP IIb/IIIa inhibitor did not modify our results.
Only a few studies have described the clinical implications of biological resistance to clopidogrel. Matetzky et al. [7] assessed ADP-induced platelet aggregation in 60 patients undergoing stenting for acute ST-elevation myocardial infarction. Patients in the highest quartile (quartile 4) of clopidogrel responsiveness were defined as low responders and were at increased risk of cardiovascular events after discharge. Cuisset et al. [18] also reported the prognostic importance of low platelet response to dual antiplatelet therapy in patients with an ACS. Recently, Price et al. [19] demonstrated with the point-of-care, a correlation between high post-treatment platelet reactivity and post-discharge events after percutaneous coronary intervention with a drug-eluting stent.
To our knowledge, the clinical implication of clopidogrel response using cytometric VASP analysis rarely has been studied. Barragan et al. [13] first showed that VASP phosphorylation analysis may be useful for the detection of coronary stent thrombosis. They found a significant difference in VASP phosphorylation analysis between 16 patients with subacute stent thrombosis (PRI = 63.28 ± 9.56) and 30 stented patients free of complications (39.80 ± 10.9%; p < 0.0001). Gurbel et al. [20] , using multiple biological methods including VASP phosphorylation, observed incomplete P2Y12 receptor inhibition in patients who suffered a subacute stent thrombosis. Patients with subacute stent thrombosis had a higher PRI of VASP (69 ± 5%) compared to those without (46 ± 9%), suggesting that a high PRI of VASP is a risk factor for development of subacute stent thrombosis.
In our study, patients were administered a 300 mg loading dose of clopidogrel followed by 75 mg per day. This loading dose is effective [21] but requires a long interval to achieve its peak effect [22] . A loading dose of 600 or 900 mg may overcome this limitation [22, 23] . We also tried to establish an initial cut-off of PRI of VASP that selects patients at risk of cardiovascular events at 6 months in our clopidogrel regimen. Our data suggest that a good response to clopidogrel therapy is associated with the absence of subsequent cardiovascular events. However, our cut-off value needs to be tested in a large randomized study, in particular using a higher loading dose of clopidogrel.
Limitations
This study is limited by its small sample size and heterogeneous ACS population. Irrespective of whether the patients underwent revascularization or medical treatment only, all received clopidogrel. Nevertheless, we purposefully chose a ''real-world'' approach. Failure to adhere to clinical guidelines concerning the use of GP IIb/IIIa inhibitors, which were used in only a fraction of high-risk patients, represents another limitation to our study.
When using standard loading doses, early flow-cytometric assessment of VASP phosphorylation does not appear to be able to evaluate response to clopidogrel. Rather, the value of this test emerges after 4 days of clopidogrel treatment. Although this may be viewed as a limitation in clinical practice, the test does detect high-risk patients before discharge from hospital. However, the recent increase in loading dose of clopidogrel may allow for earlier evaluation of clopidogrel response using VASP phosphorylation but this remains to be confirmed.
Conclusion
When using a 300 mg loading dose of clopidogrel followed by 75 mg per day, the VASP index can be used to identify low responders to clopidogrel therapy who are at higher risk of vascular events. The data from this study suggest that the optimal time to determine the PRI of VASP index is likely to be at least 48 hours after the clopidogrel loading dose has been administered.
